国产91福利在线,久久久997,EEUSS午夜中文

Tsinghua Develops Long-Lived CAR-T Cells for Single-Dose Obesity & Diabetes Therapy Semaglutide Tsinghua University develops long-lived CAR-T cells that enable single-dose, long-term treatment of obesity and diabetes, offering a potential one-time therapy for chronic diseases.
ASCO 2025: Latest Clinical Advances in Solid Tumor CAR-T Therapies from China and the U.S. ASCO Explore key updates from ASCO 2025 on solid tumor CAR-T therapies, including clinical trial data from leading Chinese firms and U.S. companies like A2 Bio, showcasing promising safety and efficacy results.
Age-associated NAD Decline Drives CAR-T Cell Therapy Failure CAR-T Aging-related decline in NAD levels impairs CAR-T cell therapy effectiveness. Restoring NAD metabolism enhances mitochondrial function and offers a promising strategy to improve CAR-T treatment outcomes in elderly patients.
BAFF-R CAR-T: CR 100% CAR-T PeproMene Bio's BAFF-R targeted CAR-T therapy PMB-CT01 shows 100% complete response in Phase 1 trials for B-cell lymphomas and leukemia, offering promising, durable results with manageable safety.
Q1 Sales Surge for CAR-T Therapies: Up to 146% Market Trend GuideView reviews the Q1 2025 sales performance of six FDA-approved CAR-T cell therapies. Highlights include Breyanzi’s 146% surge and Carvykti’s 135% rise, while Kymriah and Tecartus saw declines.
Stylus Medicine Raises $85 Million! Eli Lilly Stylus Medicine raises $85M to develop in vivo CAR-T cell therapies, targeting gene insertion, non-viral DNA delivery, and cell therapy solutions with backing from Eli Lilly, Johnson & Johnson, and others.
Cell Research: First Use of Off-the-Shelf Allogeneic CAR-T Therapy for SLE in China CAR-T Chinese researchers have successfully treated refractory systemic lupus erythematosus (SLE) using off-the-shelf allogeneic CAR-T therapy, demonstrating safety and efficacy. This breakthrough offers a promising approach for autoimmune diseases.
2024 Global CAR-T Sales Performance CAR-T Discover the sales performance of CAR-T therapies in 2024, including Kymriah, Yescarta, Breyanzi, and more. Explore trends, growth, and challenges in the CAR-T cell therapy market across the US and beyond.
In Vivo CAR-T: A New Horizon CAR-T Explore the promising future of in vivo CAR-T therapy, a breakthrough in cancer and autoimmune disease treatment. Companies like Interius and Umoja are leading the way with innovative in vivo CAR-T therapies targeting CD19, CD20, and CD22. Discover the latest advances and clinical trials.

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水